Talaris Therapeutics, Inc. announced Dr. Suzanne Ildstad, Chief Scientific Officer and Founder, to become Senior Scientific Advisor. Effective August 31, 2022, Dr. Ildstad will transition from her current role as CSO to being a Senior Scientific Advisor to Talaris. Dr. Ildstad will continue to advise the company on key scientific matters, remain on Talaris' Scientific Advisory Board and continue as a member of Talaris' Board of Directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.91 USD | +0.14% | +2.20% | -46.87% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.87% | 356M | |
+18.72% | 123B | |
+14.53% | 107B | |
-2.88% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-11.83% | 16.23B | |
+1.46% | 13.43B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- TRML Stock
- News Tourmaline Bio, Inc.
- Talaris Therapeutics, Inc. Announces Transition of Suzanne Ildstad as CSO to Being A Senior Scientific Advisor, Effective to Being A Senior Scientific Advisor